Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

P3 Health Partners (PIIIW) EBITDA Margin (2020 - 2025)

P3 Health Partners' EBITDA Margin history spans 6 years, with the latest figure at 39.85% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 268.0% year-over-year to 39.85%; the TTM value through Dec 2025 reached 18.37%, up 284.0%, while the annual FY2025 figure was 18.37%, 284.0% up from the prior year.
  • EBITDA Margin reached 39.85% in Q4 2025 per PIIIW's latest filing, down from 12.66% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 28.72% in Q4 2021 to a low of 827.09% in Q1 2021.
  • Average EBITDA Margin over 5 years is 80.97%, with a median of 16.98% recorded in 2021.
  • The largest YoY upside for EBITDA Margin was 80824bps in 2022 against a maximum downside of -33379bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 28.72% in 2021, then plummeted by -823bps to 207.56% in 2022, then skyrocketed by 91bps to 18.38% in 2023, then plummeted by -102bps to 37.18% in 2024, then fell by -7bps to 39.85% in 2025.
  • Per Business Quant, the three most recent readings for PIIIW's EBITDA Margin are 39.85% (Q4 2025), 12.66% (Q3 2025), and 9.42% (Q2 2025).